Skip to main content
OpenTrials

Clinical trial condition

Infections, Meningococcal

Explore clinical trials studying Infections, Meningococcal. Study availability and eligibility vary by location and protocol.

65 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Infections, Meningococcal trial results

Completed

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

NCT02212457

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Jonesboro, Arkansas, United States
  • GSK Investigational Site Hialeah, Florida, United States
  • GSK Investigational Site Melbourne, Florida, United States
  • GSK Investigational Site Augusta, Kansas, United States
View all 32 locations
View Trial Details
Completed

Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations

NCT02446691

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Ansan-si, South Korea
  • GSK Investigational Site Incheon, South Korea
  • GSK Investigational Site Jeonju, South Korea
  • GSK Investigational Site Seongnam-si, South Korea
View Trial Details
Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

NCT00718666

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +12 more
Locations
  • GSK Investigational Site Benton, Arkansas, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Antioch, California, United States
  • GSK Investigational Site Fremont, California, United States
View all 14 locations
View Trial Details
Completed

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

NCT00471081

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Benton, Arkansas, United States
  • GSK Investigational Site Little Rock, Arkansas, United States
  • GSK Investigational Site Antioch, California, United States
View all 19 locations
View Trial Details
Completed

Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children

NCT01900899

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Espoo Vaccine Research Clinic Espoo, Finland
  • Tampereen yliopisto/ Etela-Helsingin rokotetutkimusklinikka Helsinki, Finland
  • Helsinki East Vaccine Research Clinic Helsinki, Finland
  • Tampereen Yliopisto/ Jarvenpaan rokotetutkimusklinikka Jarvenpaa, Finland
View Trial Details
Completed

Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.

NCT01682876

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +5 more
Locations
  • GSK Investigational Site Birmingham, Alabama, United States
  • GSK Investigational Site Sacramento, California, United States
  • GSK Investigational Site Lake Mary, Florida, United States
  • GSK Investigational Site Marietta, Georgia, United States
View all 19 locations
View Trial Details
Completed

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

NCT01962207

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Espoo Vaccine Research Clinic Espoo, Finland
  • South Helsinki Vaccine Research Clinic Helsinki, Finland
  • Helsinki East Vaccine Research Clinic Helsinki, Finland
  • Jarvenpaa Vaccine Research Clinic Jarvenpaa, Finland
View Trial Details
Completed

Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination

NCT01777308

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • GSK Investigational Site Garran, Australian Capital Territory, Australia
  • GSK Investigational Site Randwick, New South Wales, Australia
  • GSK Investigational Site Westmead, New South Wales, Australia
  • GSK Investigational Site Herston, Queensland, Australia
View Trial Details

Related conditions